 MethodologyCorrection: RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genesTatjana C Gust1  , Luisa Neubrandt1 , Claudia Merz2 , Khusru Asadullah2 , Ulrich Zügel1 and Arne von Bonin1  1Common Mechanism Research, Global Drug Discovery, Bayer Schering Pharma AG, Muellerstrasse 178, 13342 Berlin, Germany 2Target Discovery, Global Drug Discovery, Bayer Schering Pharma AG, Muellerstrasse 178, 13342 Berlin, Germany  author email corresponding author email
Cell Communication and Signaling 2008,
6:3doi:10.1186/1478-811X-6-3 Abstract
T cells play a central role in many inflammatory diseases, hence the identification and validation of T cell-specific target genes will increase the understanding of T cell function in pathologic inflammatory situations. RNA interference (RNAi), with its ability to induce specific gene silencing in mammalian cells, represents a powerful technology to investigate and validate the function of pharmaceutical target genes in vitro and in vivo. The aim of the present study was to systematically explore RNAi-mediated gene-silencing of known T cell-specific model signaling molecules in primary murine T cells in vitro and in vivo. We demonstrate that siRNA delivery and subsequent silencing of T cell specific genes is substantially increased, if murine T cells were activated prior siRNA transfection. Silencing of ZAP70, p56Lck as well as PLC-γ1 protein expression resulted in impaired function of T cells in vitro. Furthermore, delayed type hypersensitivity (DTH) was ameliorated in vivo after adoptive transfer of ZAP70-silenced T cells. The combination of RNAi-mediated gene silencing and adoptive transfer of gene-silenced T cells, thus, may allow the identification and analysis of T cell-specific targets for therapeutic intervention. Additionally, this model system may represent an alternative to conventional time consuming and cost intensive gene targeting approaches. | 
on Google Scholar
